Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions
MONDO:0006397A group of kidney carcinomas characterized by the presence of different translocations involving the chromosome Xp11.2. These translocations result in the creation of gene fusions involving the TFE3 gene. Patients are usually children and young adults. Morphologically, the malignant epithelial cells form papillary patterns.
Also known as: TFE3-Rearranged renal cell carcinoma, Xp11.2 translocation-related renal cell carcinoma, renal cell cancer associated with Xp11.2 translocations/TFE3 Gene fusions, renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, tRCC, translocation-associated renal cell carcinoma
2783 clinical trials for this condition and its sub-types, 7 tagged with Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Triple therapy takes on rare, aggressive kidney cancer
Disease control Not yet recruitingThis phase II trial tests a combination of two immunotherapies (ipilimumab and sintilimab) plus a targeted drug (lenvatinib) as a first treatment for people with a rare and aggressive form of kidney cancer called TFE3-rearranged renal cell carcinoma. The study enrolls about 66 pa…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug elranatamab tested in Real-World chinese myeloma patients
Disease control Not yet recruitingThis study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC